Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

BACKGROUND: The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level. METHODS: Peripheral blood mononuclear cells from healthy donors were incubated with different JAKis, levels of phospho...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B., Byers, Nicole L., Higgs, Richard E., Lee, Jonathan, Macias, William L., Na, Songqing, Ortmann, Robert A., Rocha, Guilherme, Rooney, Terence P., Wehrman, Thomas, Zhang, Xin, Zuckerman, Steven H., Taylor, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679539/
https://www.ncbi.nlm.nih.gov/pubmed/31375130
http://dx.doi.org/10.1186/s13075-019-1964-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679539/
https://www.ncbi.nlm.nih.gov/pubmed/31375130
http://dx.doi.org/10.1186/s13075-019-1964-1

Ejemplares similares